Congratulations to the Hemostasis Study Group and the Neurological Complications Study Group: the winners of this year’s Outstanding Study Group Award!
Hemostasis Study Group
Outstanding Study Group Leader: Carmen Escalante (Study Group Chair)
Despite being one of our smaller study groups, the Hemostasis Study Group has been exceptionally active in recent years, with key accomplishments including:
- A collection of 11 articles on hemostasis in cancer to be published in the coming months in Supportive Care in Cancer
- Paper on Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care and Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper (joint publication with the Neutropenia, Infection & Myelosuppression Study Group)
- A 2021 webinar on Cancer-Associated Thrombosis (CAT) in COVID-19 Era
- Numerous parallel sessions and workshops hosted at recent Annual Meetings
- A MASCC guideline currently under development (led by Dr Taylor Butler)
- A clinical study underway on adherence and quality of life in people with cancer on anticoagulation (led by Dr Cristhiam Rojas-Hernandez)
We are delighted to be able to recognize these many accomplishments under the leadership of Dr Carmen Escalante, whose dedication, hard work and leadership were essential to the study group’s success.
Neurological Complications Study Group
Outstanding Study Group Leader Award: Mary Tanay
One of the key strengths of the Neurological Complications Study Group has been providing leadership opportunities for junior members to showcase their work. For that reason, it’s not surprising that the Outstanding Study Group Leader Award goes to Mary Tanay, a younger member who has done an exceptional job leading the MASCC Neuropathy International Study, which has currently collected close to 500 responses.
Other key study group accomplishments include:
- The publication of Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy, our newest MASCC book
- Papers on Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) published in Cancer Treatment Reviews and Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group published in Supportive Care in Cancer
- Two webinars hosted in 2021: Cancer-Related Cognitive Impairment and Chemotherapy-Induced Peripheral Neuropathy (CIPN) Assessment Training
- A 2022 Annual Meeting parallel session hosted in collaboration with the Mucositis Study Group
- A workshop planned for early 2023 on Pre-Clinical and Clinical Perspectives of Physical Exercise for The Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
- A manuscript under preparation on the topic of neurological imaging
The Outstanding Study Group Award is designed to recognize a study group’s excellence and achievement in promoting, activating, and executing activity within the study group. The Outstanding Study Group Leader Award recognizes the efforts of the principal driver of the main project that led to the Study Group’s recognition and award.
